Reporting of adverse events and statistical details of efficacy estimates in randomized clinical trials of pain in temporomandibular disorders: Analgesic, anesthetic, and addiction clinical trial translations, innovations, opportunities, and networks systematic review

Journal of the American Dental Association

Volumn 146, Issue 4, 2015, Pages 246-254.e6

  Gewandter, Jennifer S ^a   Smith, Shannon M ^a   McKeown, Andrew ^a   Edwards, Kenessa ^a   Narula, Aastha ^b   Pawlowski, Joseph R ^a   Rothstein, Daniel ^a   Desjardins, Paul J ^c,d   Dworkin, Samuel F ^e   Gross, Robert A ^a   Ohrbach, Richard ^f   Rappaport, Bob A ^g   Sessle, Barry J ^h   Turk, Dennis C ^e   Dworkin, Robert H ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c Desjardins Assoc   (United States)

^d TUFTS UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY AT BUFFALO   (United States)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

Addiction Clinical Trial Translations; Analgesic; Anesthetic; Clinical trials; Harms reporting; Innovations; Missing data; Multiplicity; Networks; Opportunities; Temporomandibular disorder

Indexed keywords

ANALGESIC AGENT;

ARTHRALGIA; COMPLICATION; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; TEMPOROMANDIBULAR JOINT DISORDERS; TREATMENT OUTCOME;

ANALGESICS; ARTHRALGIA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TEMPOROMANDIBULAR JOINT DISORDERS; TREATMENT OUTCOME;

EID: 84932183040     PISSN: 00028177     EISSN: 19434723     Source Type: Journal    
DOI: 10.1016/j.adaj.2014.12.023     Document Type: Review

References (45)

1. American Academy of Orofacial Pain. Orofacial Pain: Guidelines for Assessment, Diagnosis, and Management. 5th ed. Hanover Park, IL: Quintessence Publishing; 2013.
2. Wright EF, North SL. Management and treatment of temporomandibular disorders: a clinical perspective. J Man Manip Ther. 2009;17(4):247-254.
3. Truelove E, Huggins KH, Mancl L, Dworkin SF. The efficacy of traditional, low-cost and nonsplint therapies for temporomandibular disorder: a randomized controlled trial. JADA. 2006;137(8):1099-1107.
4. American Academy of Oral and Maxillofacial Surgeons. Temporomandibular disorders. Available at: http://www.aaoms.org/docs/practice-mgmt/condition-statements/tmj-disorders.pdf. Accessed August 20, 2008.
5. Liu F, Steinkeler A. Epidemiology, diagnosis, and treatment of temporomandibular disorders. Dent Clin North Am. 2013;57(3):465-479.
6. Bauer P, Chi G, Geller N, et al. Industry, government, and academic panel discussion on multiple comparisons in a "real" phase three clinical trial. J Biopharm Stat. 2003;13(4):691-701.
7. Committee for Proprietary Medicinal Products. Points to consider on multiplicity issues in clinical trials. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003640.pdf. Accessed January 15, 2015.
8. European Medicines Agency. Guideline on missing data in confirmatory clinical trials. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/09/WC500096793.pdf. Accessed January 15, 2015.
9. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14): 1355-1360.
10. Molenbergs G, Kenward MG. Missing Data in Clincal Studies. Chichester, UK: Wiley; 2007.
11. Panel on Handling Missing Data in Clinical Trials; National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. Washington, DC: National Academies Press; 2010. Available at: http://www.nap.edu/openbook.php?record-id=12955. Accessed January 22, 2015.
12. O'Neill RT, Temple R. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clin Pharmacol Ther. 2012;91(3):550-554.
13. Pocock SJ. Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. Control Clin Trials. 1997;18(6):530-545.
14. Sankoh AJ, D'Agostino RB Sr, Huque MF. Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues. Stat Med. 2003;22(20):3133-3150.
15. Turk DC, Dworkin RH, McDermott MP, et al. Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations - Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials. Pain. 2008;139(3):485-493.
16. US Department of Health and Human Services Food and Drug Administration. Guidance for industry: E9 statistical principles for clinical trials. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073137.pdf. Accessed January 15, 2015.
17. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865-869.
18. Edwards JE, McQuay HJ, Moore RA, Collins SL. Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. J Pain Symptom Manage. 1999;18(6):427-437.
19. Ioannidis JP, Mulrow CD, Goodman SN. Adverse events: the more you search, the more you find. Ann Intern Med. 2006;144(4):298-300.
20. Rief W, Barsky AJ, Glombiewski JA, et al. Assessing general side effects in clinical trials: reference data from the general population. Pharmacoepidemiol Drug Saf. 2011;20(4):405-415.
21. Rief W, Nestoriuc Y, von Lilienfeld-Toal A, et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf. 2009;32(11):1041-1056.
22. Tugwell P, Judd MG, Fries JF, Singh G, Wells GA. Powering our way to the elusive side effect: a composite outcome 'basket' of predefined designated endpoints in each organ system should be included in all controlled trials. J Clin Epidemiol. 2005;58(8):785-790.
23. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134(8):663-694.
24. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA. 1996;276(8):637-639.
25. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781-788.
26. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
27. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Guyatt GH. The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist. Control Clin Trials. 2002;23(4):380-388.
28. Haidich AB, Birtsou C, Dardavessis T, Tirodimos I, Arvanitidou M. The quality of safety reporting in trials is still suboptimal: survey of major general medical journals. J Clin Epidemiol. 2011;64(2):124-135.
29. Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed. BMJ. 2010;340:c723.
30. Kane RL, Wang J, Garrard J. Reporting in randomized clinical trials improved after adoption of the CONSORT statement. J Clin Epidemiol. 2007;60(3):241-249.
31. Mills EJ, Wu P, Gagnier J, Devereaux PJ. The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement. Contemp Clin Trials. 2005;26(4):480-487.
32. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA. 2001;285(15):1992-1995.
33. Gewandter JS, Smith SM, McKeown A, et al. Reporting of primary analyses and multiplicity adjustment in recent analgesic clinical trials: ACTTION systematic review and recommendations. Pain. 2014;155(3):461-466.
34. Gewandter JS, McDermott MP, McKeown A, et al. Reporting of missing data and methods used to accommodate them in recent analgesic clinical trials: ACTTION systematic review and recommendations. Pain. 2014;155(9):1871-1877.
35. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;319(7211):670-674.
36. Huic M, Marusic M, Marusic A. Completeness and changes in registered data and reporting bias of randomized controlled trials in ICMJE journals after trial registration policy. PLoS One. 2011;6(9):e25258.
37. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med. 2009;169(19):1756-1761.
38. Shukralla AA, Tudur-Smith C, Powell GA, Williamson PR, Marson AG. Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms. Epilepsy Res. 2011;97(1-2):20-29.
39. Smith SM, Chang RD, Pereira A, et al. Adherence to CONSORT harms-reporting recommendations in publications of recent analgesic clinical trials: an ACTTION systematic review. Pain. 2012;153(12):2415-2421.
40. Smith SM, Wang AT, Katz NP, et al. Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154(7):997-1008.
41. Hunsinger M, Smith SM, Rothstein D, et al. Adverse event reporting in nonpharmacologic, noninterventional pain clinical trials: ACTTION systematic review. Pain. 2014;155(11):2253-2262.
42. Romero-Reyes M, Uyanik JM. Orofacial pain management: current perspectives. J Pain Res. 2014;7:99-115.
43. Miettinen O, Lahti S, Sipila K. Psychosocial aspects of temporomandibular disorders and oral health-related quality-of-life. Acta Odontol Scand. 2012;70(4):331-336.
44. Fillingim RB, Ohrbach R, Greenspan JD, et al. Potential psychosocial risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case-control study. J Pain. 2011;12(11 suppl):T46-T60.
45. Ohrbach R, Fillingim RB, Mulkey F, et al. Clinical findings and pain symptoms as potential risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case-control study. J Pain. 2011;12(11 suppl):T27-T45.